The radium-223 expanded access clinical trial

Just a quick update to information about expanded access to treatment with radium-223 — the injectable form of radiation therapy currently being developed by Bayer Healthcare and Algeta. … READ MORE …

Expanded access trial in development for radium-223 chloride (Alpharadin) in mCRPC

We have heard from one of our contacts that Bayer Healthcare (presumably in combination with their business partner, Algeta) is initiating an expanded access (compassionate use) trial of injectable radiation therapy with radium-223 chloride (Alpharadin®) for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …